Novartis announced its intention to separate its generics and biosimilar division, Sandoz, into a new publicly traded standalone company through...
Novartis
A new hope is looming for Myelofibrosis patients who experienced a suboptimal response to ruxolitinib and those who were JAK...
Tisagenlecleucel, sold under the brand name Kymriah was the first gene therapy approved by the FDA on 30 August 2017....
Pfizer has agreed to acquire Global Blood Therapeutics for $5.4 billion. Based on this, Global Blood Therapeutics will hand its...
Several indications and molecules were approved in October by FDA including the following: 1- Brexucabtagene autoleucel for adult patients with...
